Search Results
Your search for ,wAs matches 27467 pages
Showing 8151 - 8200Ixazomib/Rituximab/Dexamethasone for Relapsed or Refractory Waldenström’s Macroglobulinemia
In a phase I/II trial (HOVON124/ECWM-R2) reported in the Journal of Clinical Oncology, Kersten et al found that the combination of oral ixazomib with subcutaneous rituximab and dexamethasone showed efficacy in patients with relapsed or refractory Waldenström’s macroglobulinemia, with a manageable...
Cancer Predisposition Screening Tool for Predicting Subsequent Malignancies in Childhood Cancer Survivors
In a Canadian study reported in the Journal of Clinical Oncology, Cullinan et al found that the McGill Interactive Pediatric OncoGenetic Guidelines (MIPOGG) tool provided predictive value for risk of subsequent malignant neoplasms in childhood cancer survivors beyond risk associated with treatment...
Japanese Study Examines How Intervention Encourages Screening for Colorectal Cancer Among Patients With Schizophrenia
Cancer is a leading cause of mortality in patients with mental illnesses. Although individuals with mental illnesses are equally as vulnerable to cancer as the general population, they are at a much higher risk of cancer-related mortality. Owing to a lack of early screening in most cases, such...
Antihypertensive Medications May Improve Survival Among Patients With Stage I to III Colorectal Cancer
Commonly used blood pressure drugs may improve survival for patients with colorectal cancer, a recent study published by Balkrishnan et al in Cancer Medicine suggests. After reviewing outcomes of almost 14,000 patients with colorectal cancer, researchers determined that angiotensin-converting...
Report Aims to Assess Contemporary Burden of Brain Tumors in the United States
A new study found that incidence rates for malignant brain and other central nervous system (CNS) tumors declined by 0.8% annually during 2008 through 2017 in the United States for all ages combined. The decline was driven by trends in adults, whereas rates have slightly increased by 0.5% to 0.7%...
Does Radiotherapy Reduce the Long-Term Risk of Ipsilateral Breast Recurrence in Women With DCIS Who Underwent Lumpectomy?
In an analysis of long-term outcomes from the phase III NRG/RTOG 9804 trial reported in the Journal of Clinical Oncology, Beryl McCormick, MD, and colleagues found that whole-breast irradiation vs observation was associated with reduced risk of all and invasive ipsilateral breast recurrence at 15...
Profile of Adverse Events Related to PD-1 and PD-L1 Inhibitor–Based Therapy
In a systematic review and meta-analysis reported in The Lancet Oncology, Zhou et al provided a profile of treatment-related adverse events observed in clinical trials combining PD-1 or PD-L1 inhibitors with chemotherapy, targeted therapy, immunotherapy, and radiotherapy. Study Details The...
FDA Approves Ivosidenib for Advanced or Metastatic IDH1-Mutated Cholangiocarcinoma
On August 25, the U.S. Food and Drug Administration (FDA) approved ivosidenib (Tibsovo), a small-molecule inhibitor of isocitrate dehydrogenase-1 (IDH1), for adult patients with previously treated locally advanced or metastatic cholangiocarcinoma with an IDH1 mutation as detected by an FDA-approved ...
Study Finds Evidence-Based Interventions Added to Screening Did Not Improve Cancer Pain
When added to regular screening and guidelines, evidence-based interventions implemented at the patient, health professional, and service levels did not significantly improve cancer pain, according to research led by Melanie Lovell, MBBS, PhD, Medical Head of Palliative Care at HammondCare and...
ASCO and MASCC/ISOO Publish Joint Guideline on Prevention, Treatment of Salivary Gland Hypofunction and Xerostomia
A new joint ASCO guideline offers clinicians updated evidence-based recommendations for the prevention and treatment of salivary gland hypofunction and xerostomia caused by nonsurgical cancer therapies.1 The guidance was developed together by ASCO and the Multinational Association of Supportive...
Leland Chung, PhD, Distinguished Mentor and Urologic Oncology Research Scientist, Dies at 80
Talk to anyone who knew Leland Chung, PhD, and you’ll hear the same descriptions of the famed scientist: warm, humble, gracious, brilliant, innovative. Dr. Chung, who served as Director of the Urologic Oncology Research Program at Cedars-Sinai Cancer in Los Angeles for 12 years and was Professor in ...
I’m a Two-Time Breast Cancer Survivor, and the Experience Has Been Life-Altering
Even before my breast cancer diagnosis in early 2002, the year was shaping up to be life-altering for me and my family. We had moved from Seattle to Houston for a new career opportunity for my husband and were just settling into our new home when I felt a pea-sized nodule in my left breast during a ...
Neuroendocrine Tumor Specialist Pamela Kunz, MD, Looks to Promote Equity in the Workforce
In this installment of the Living a Full Life series, guest editor Jame Abraham, MD, spoke with Pamela Kunz, MD, Director, Center for Gastrointestinal Cancers at Smilow Cancer Hospital and Yale Cancer Center. Dr. Kunz is an international leader in the clinical care of patients with neuroendocrine...
Sacituzumab Govitecan-hziy for Locally Advanced or Metastatic Triple-Negative Breast Cancer
On April 7, 2021, sacituzumab govitecan-hziy was granted regular approval for treatment of patients with unresectable locally advanced or metastatic triple-negative breast cancer who have received two or more prior systemic therapies, at least one of them for metastatic disease.1 Sacituzumab...
Sacituzumab Govitecan-hziy for Locally Advanced or Metastatic Urothelial Cancer
On April 13, 2021, sacituzumab govitecan-hziy was granted accelerated approval to treat patients with locally advanced or metastatic urothelial cancer who had received platinum-containing chemotherapy and either a PD-1 or a PD-L1 inhibitor.1 Supporting Efficacy Data Approval was based on findings...
Belumosudil for Chronic Graft-vs-Host Disease
On July 16, 2021, belumosudil, an inhibitor of Rho-associated coiled-coil kinase 2, was approved for the treatment of adult and pediatric patients 12 years and older with chronic graft-vs-host disease after the failure of at least two prior lines of systemic therapy.1 Supporting Efficacy Data...
High Prevalence of Previously Undiagnosed Emphysema Among Individuals Undergoing Low-Dose CT Screening for Lung Cancer
In a prospective cohort study reported in Clinical Imaging, David Steiger, MD, of the Division of Pulmonary, Critical Care and Sleep Medicine, Icahn School of Medicine at Mount Sinai, in New York, and colleagues in the International Early Lung Cancer Action Program (I-ELCAP) identified emphysema in ...
New Guideline Provides Clarity on Timing, Treatment of Axilla in Early-Stage Breast Cancer
ASCO and Ontario Health (Cancer Care Ontario) have collaborated to release a new clinical practice guideline on the management of the axilla in early-stage breast cancer.1 “A lot has changed in the past several years with regard to de-escalating the amount of treatment women are offered in the...
Isatuximab-irfc in Relapsed or Refractory Multiple Myeloma
On March 31, 2021, the anti-CD38 monoclonal antibody isatuximab-irfc was approved for use in combination with carfilzomib and dexamethasone for the treatment of adults with relapsed or refractory multiple myeloma who have received one to three prior lines of therapy.1 Supporting Efficacy Data...
Vanderbilt University Appoints Karen Winkfield, MD, PhD, Professor of Radiation Oncology
Karen Winkfield, MD, PhD, Executive Director, Meharry-Vanderbilt Alliance, and Ingram Professor of Cancer Research, was recently promoted to Professor of Radiation Oncology at Vanderbilt University Medical Center (VUMC). “Grateful to those who paved the way,” said Dr. Winkfield on Twitter, noting...
Historic, Present, and Future Perspectives on Breast Cancer in Egypt
Breast cancer is the most frequently diagnosed cancer among women around the world, making it a significant public health problem.1 The disease affects both men and women, although it is rare in men, accounting for just 1% of all breast cancer diagnoses in the United States and less than 0.1% of...
Low-Dose CT Screening for Lung Cancer and the Incidental Findings That May Improve Future Health
Every interaction with patients is an opportunity to change the course of their lives. In the context of screening for disease, every encounter is an opportunity to detect the precursors or early changes that signal early pathophysiology. Smoking status and age are the factors that currently...
Axicabtagene Ciloleucel Improves Multiple Clinical Endpoints in Relapsed Follicular Lymphoma
For the treatment of relapsed or refractory follicular lymphoma, updated data from the ZUMA-5 trial, as compared with the findings of the external control cohort of SCHOLAR-5, showed substantial improvement in all key clinical endpoints with axicabtagene ciloleucel, ZUMA-5 investigators reported in ...
FDA Pipeline: Reviews for Agents in Acute Graft-vs-Host Disease, Nasopharyngeal and Ovarian Cancers
Recently, the U.S. Food and Drug Administration (FDA) granted Priority Review to an agent for the prevention of acute graft-vs-host disease; Breakthrough Therapy designation to an anti–PD-1 monoclonal antibody for the treatment of metastatic nasopharyngeal carcinoma; and Fast Track designation to a ...
Study Examines Link Between Obesity in Long-Term Cancer Survivors and Increased Health-Care Utilization and Spending
A new study from the American Cancer Society published by Xuesong Han, PhD, and colleagues in the journal Cancer has found a link between obesity and the substantial economic burden of nearly $20 billion in 2016 among long-term cancer survivors in the United States, with one-third attributable to...
Patients With Melanoma Previously Treated With PD-1 or MAPK Inhibitors May Be Less Likely to Respond to ACT-TIL Therapy
Patients with metastatic melanoma who were previously treated with PD-1 or MAPK inhibition are significantly less likely to develop durable objective responses to adoptive cell transfer of tumor-infiltrating lymphocytes (ACT-TIL) than patients naive to these treatments, according to a study...
Adjuvant Pembrolizumab May Improve Disease-Free Survival in Patients With High-Risk Renal Cell Carcinoma
As reported in The New England Journal of Medicine by Toni K. Choueiri, MD, and colleagues, an interim analysis of the phase III KEYNOTE-564 trial showed improved disease-free survival with adjuvant pembrolizumab vs placebo after nephrectomy in high-risk patients with clear cell renal cell...
Non–Testicular Cancer Mortality Rates in Men With Testicular Cancer in the Cisplatin Era
In a Norwegian population-based study reported in the Journal of Clinical Oncology, Hellesnes et al found that treatment of testicular cancer with platinum-based chemotherapy or radiotherapy was associated with a significant excess of non–testicular cancer mortality compared with the general...
Extended Follow-up of PALOMA-3 Supports Survival Benefit of Palbociclib Plus Fulvestrant in Advanced Breast Cancer
An updated analysis of the PALOMA-3 randomized, placebo-controlled trial demonstrated continued superiority for the combination of palbociclib (CDK4/6 inhibitor) plus fulvestrant over fulvestrant plus placebo in women with hormone receptor–positive, HER2-negative advanced breast cancer whose...
PD-L1–Positive Non–Small Cell Lung Cancer
In this video, Drs. Justin F. Gainor, Ibiayi Dagogo-Jack, and Jyoti D. Patel discuss current therapy options for PD-L1–positive non–small cell lung cancer (NSCLC). Dr. Gainor presents the case of a 65-year-old man with 55-year smoking history who was diagnosed with stage II NSCLC. The faculty...
ALK-Positive Non–Small Cell Lung Cancer
In this video, Drs. Justin F. Gainor, Ibiayi Dagogo-Jack, and Jyoti D. Patel discuss current treatment options for ALK fusion–positive non–small cell lung cancer (NSCLC). Dr. Gainor presents the case of a 31-year-old patient with minimal tobacco exposure who was diagnosed with metastatic NSCLC....
NTRK Fusion–Positive Non–Small Cell Lung Cancer
In this video, Drs. Justin F. Gainor, Ibiayi Dagogo-Jack, and Jyoti D. Patel discuss the management of NTRK fusion–positive non–small cell lung cancer (NSCLC). Dr. Gainor presents the case of a 44-year-old man with a 5 pack-year history of tobacco exposure who was diagnosed with metastatic NSCLC;...
RET Fusion–Positive Non–Small Cell Lung Cancer
In this video, Drs. Justin F. Gainor, Ibiayi Dagogo-Jack, and Jyoti D. Patel discuss the management of RET fusion–positive non–small cell lung cancer (NSCLC). The case presented is a 65-year-old never-smoker patient with metastatic NSCLC who was found to have an EGFR A118V mutation and a KIF5B-RET...
FDA Grants Approval to the Pfizer-BioNTech COVID-19 Vaccine
On August 23, the U.S. Food and Drug Administration (FDA) approved the first COVID-19 vaccine. The vaccine has been known as the Pfizer-BioNTech COVID-19 vaccine, and will now be marketed as Comirnaty, for the prevention of COVID-19 disease in individuals aged 16 years and older. The vaccine also...
Excess Cardiovascular Disease Risk in Patients With Early-Stage Lymphoma: Personalizing Radiotherapy Delivery
As reported in the Journal of Clinical Oncology by Cutter et al, an analysis from the UK NCRI RAPID trial of positron-emission tomography (PET)-directed therapy in patients with early-stage Hodgkin lymphoma indicated that the use of involved-field radiotherapy in PET-negative patients who had...
Combination of Lenvatinib and Etoposide/Ifosfamide for Relapsed or Refractory Osteosarcoma
In the phase I/II ITCC-050 trial reported in The Lancet Oncology, Gaspar et al found that the combination of lenvatinib with etoposide/ifosfamide showed antitumor activity, including good progression-free survival outcomes, in patients with relapsed or refractory osteosarcoma. Study Details...
Physical Activity and Cognitive Function Before, During, and After Chemotherapy for Breast Cancer
In a study reported in the Journal of Clinical Oncology, Elizabeth A. Salerno, PhD, MPH, and colleagues found that higher levels of physical activity before and during chemotherapy in women with early-stage breast cancer was associated with better cognitive function outcomes at up to 6 months...
FDA Approves Nivolumab for Adjuvant Treatment of Urothelial Carcinoma
On August 19, the U.S. Food and Drug Administration (FDA) approved the anti–PD-1 therapy nivolumab (Opdivo) for the adjuvant treatment of patients with urothelial carcinoma who are at high risk of disease recurrence after undergoing radical resection. This is the first FDA approval for adjuvant...
Outcomes Notably Improving for Adult ALL
Outcomes in adults with acute lymphoblastic leukemia (ALL) are almost rivaling those in pediatric ALL, thanks to the benefits achieved by incorporating blinatumomab and inotuzumab into chemotherapy regimens. New ways of administering the chemotherapy component are also increasing tolerability and...
Study Examines Association Between Benign Prostatic Hyperplasia and Prostate Cancer
A team of researchers studied the relationship between benign prostatic hyperplasia (BPH) and prostate cancer in 405 men by quantitatively looking at different parts of the prostate tissue on magnetic resonance imaging (MRI). Findings from their analysis were published by Nandalur et al in the...
Early-Phase Study Rediscovers Potential Alternative to Methadone for Cancer Pain
Levorphanol was associated with improved pain and symptom control in patients with advanced cancer, according to data from an early phase I trial, reported by Akhila Reddy, MD, at the 2021 Multinational Association of Supportive Care in Cancer/International Society of Oral Oncology (MASCC/ISOO)...
Does Antibiotic Exposure Affect Response to First-Line Chemoimmunotherapy in Patients With NSCLC?
In an international, multicenter study, researchers evaluated the impact of prior and concurrent antibiotic exposure in a cohort of patients with advanced non–small cell lung cancer (NSCLC) treated with first-line chemoimmunotherapy combinations. In contrast to what has been reported in patients...
Study Identifies Possible New Genetic Biomarkers of Pediatric Leukemia
In a study published by Magnum et al in JAMA Oncology, researchers reported on how two separate DNA changes appear to predict aggressive childhood leukemias when they occur in combination. The team evaluated tumor characteristics of more than 1,300 pediatric patients with B-cell acute lymphoblastic ...
Cetuximab Plus Avelumab as Rechallenge Therapy for RAS Wild-Type Metastatic Colorectal Cancer
In an Italian phase II trial reported in JAMA Oncology, Martinelli et al found that cetuximab rechallenge plus avelumab showed activity and was well tolerated in patients with RAS wild-type metastatic colorectal cancer who had responded to first-line chemotherapy plus an anti-EGFR agent and then...
Eric Deutsch, MD, PhD, Comments on the Averectal and AVANA Trials in Rectal Cancer
Eric Deutsch, MD, PhD, Professor and Chair of Radiation Oncology at Gustave Roussy, Villejuif, France, commended the speakers for conducting trials whose results he found “very interesting.” The Averectal trial involved a short course of radiation with modified FOLFOX-6 (oxaliplatin, fluorouracil...
Avelumab Under Study as Adjunct to Neoadjuvant Therapy for Rectal Cancer
In the treatment of newly diagnosed locally advanced rectal cancer, two phase II studies evaluating the addition of the PD-L1 inhibitor avelumab to chemoradiotherapy showed promising rates of pathologic complete response, major pathologic response, and tumor downstaging. The study investigators...
Can Consumption of Vitamin D Reduce the Risk of Early-Onset Colorectal Cancer?
Consuming higher amounts of vitamin D—mainly from dietary sources—may help protect against developing young-onset colorectal cancer or precancerous colon polyps, according to the first study to show such an association. These findings were published by Kim et al in the journal Gastroenterology. The ...
Study Finds Cannabis Use Is Lower Among Patients With Cancer Than Those With No Cancer History
In a study published by Do et al in the journal Cancer, researchers analyzed data from nearly 20,000 people over a span of 4 years. They found that reports of cannabis use peaked at 9% for those with a cancer history, compared to 14% among people with no cancer history. “Even when we looked at...
First-Line Cisplatin Plus Gemcitabine or Fluorouracil for Advanced Nasopharyngeal Carcinoma: Final Overall Survival Analysis
As reported in the Journal of Clinical Oncology by Hong et al, the final overall survival analysis of the Chinese phase III GEM20110714 trial showed a significant benefit with gemcitabine/cisplatin vs fluorouracil/cisplatin as first-line treatment for recurrent or metastatic nasopharyngeal...
Donor-Derived CD7 CAR T Cells May Lead to Remissions in Patients With Relapsed or Refractory T-ALL
In a Chinese single-institution phase I study reported in the Journal of Clinical Oncology, Pan et al found that donor-derived CD7 chimeric antigen receptor (CAR) T-cell therapy produced a high complete remission rate in patients with relapsed or refractory T-cell acute lymphoblastic leukemia...
